XML 69 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets (Narrative) (Details) - USD ($)
shares in Thousands
1 Months Ended 12 Months Ended
Nov. 30, 2018
Nov. 30, 2016
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Feb. 28, 2014
Acquired Finite-Lived Intangible Assets [Line Items]            
Goodwill     $ 882,000 $ 784,000    
Other revenue, potential upfront payment related to product sales     4,800,000      
Payments to acquire businesses     5,000,000 20,000,000 $ 0  
Additions to intangible assets     772,944 3,819,486 1,213,110  
Amortization of intangible assets     4,134,557 2,769,466 $ 2,436,222  
Product and License Rights            
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible assets, gross     37,400,742 36,573,941    
Patents            
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible assets, gross     9,882,511 9,428,266    
Additions to intangible assets     700,000 400,000    
Methotrexate            
Acquired Finite-Lived Intangible Assets [Line Items]            
Payments to acquire businesses   $ 100,000        
Stock issued during period, acquisitions     900,000 $ 1,100,000    
Methotrexate | Nordic            
Acquired Finite-Lived Intangible Assets [Line Items]            
Stock issued during period, acquisitions     1,000,000.0      
Methotrexate | Restricted Stock            
Acquired Finite-Lived Intangible Assets [Line Items]            
Stock issued during period, acquisitions (in shares)   180        
VIBATIV            
Acquired Finite-Lived Intangible Assets [Line Items]            
Goodwill $ 882,000          
Payments to acquire businesses 20,000,000.0   20,000,000      
Intellectual property amortizable intangible assets $ 11,750,000          
Increase in goodwill     $ 100,000      
Vaprisol | Product and License Rights            
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible assets, gross           $ 3,000,000.0